EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
← Back to the desk

REGULATORY & SAFETY

Attach the date. Keep the boundary.

Historical milestones guide what to check next. They are not a live availability or clearance signal.

DECEMBER 2024

Tirzepatide injection shortage resolution

A historical FDA milestone. Recheck applicable current policies, legal conditions and the particular preparation.

FEBRUARY 2025

Semaglutide injection shortage resolution

A historical FDA milestone. Shortage status and patient-specific clinical questions do not collapse into a procurement clearance.

BEFORE YOUR NEXT COMMITMENT

Review current primary sources

Assign an owner to confirm federal policy, destination-state requirements, exact preparation and supplier evidence.

Create a manual review watchlist
01
Restrictions

503A vs 503B GLP-1 compounding for clinics

Separate the claimed pathway, the facility record and the proposed preparation before discussing a contract.

Primary sources attached · Specialist review pending
02
Restrictions

Can clinics still prescribe compounded semaglutide after the shortage ends?

Prescribing, compounding and dispensing are separate questions. Preserve the date and scope of any shortage-based rationale.

Primary sources attached · Specialist review pending
03
Restrictions

Compounded tirzepatide regulation for telehealth providers

Map the full multi-state arrangement, including the actual dispensing facility and the basis asserted for the preparation.

Primary sources attached · Specialist review pending
04
Restrictions

Does adding B12 establish permission to compound semaglutide?

An additional ingredient is a fact to review, not a procurement shortcut.

Primary sources attached · Specialist review pending
05
Access

LillyDirect vs pharmacy partners for weight-management clinics

Compare responsibility for the patient journey before comparing commercial headlines.

Primary sources attached · Specialist review pending
06
Access

How clinics can assess NovoCare access workflows

Keep eligibility, product presentation and patient-payment terms attached to the workflow.

Primary sources attached · Specialist review pending
07
Treatment economics

How to compare GLP-1 pharmacy quotes

Normalise the quote's identity, units, time period and payment responsibility before calculating totals.

Primary sources attached · Specialist review pending
08
Treatment economics

GLP-1 cost per patient: a clinic cost-model guide

Report both enrolled and successfully fulfilled patient-month denominators, with the payer split visible.

Primary sources attached · Specialist review pending
09
Provenance

GLP-1 pharmacy supplier due-diligence checklist

Build a claim-to-evidence register covering identity, product scope, distribution and exception handling.

Primary sources attached · Specialist review pending
10
Provenance

Verifying out-of-state pharmacy licences and dispensing coverage

Check the actual facility in each destination state's register, then assess product and operational scope separately.

Primary sources attached · Specialist review pending
11
Continuity

What to do when a GLP-1 pharmacy stops accepting prescriptions

Establish the affected operational queue, assign owners and review fallback arrangements before promising a transition.

Primary sources attached · Specialist review pending
12
Continuity

GLP-1 contract commitments, exit rights and transition questions

Turn the contract into a dated obligations register with exact excerpts and explicit calculation assumptions.

Primary sources attached · Specialist review pending

12 briefings match your filter.